Efficacy and safety of infliximab in patients with rheumatoid arthritis

National Medical Journal of China

Volumn 89, Issue 27, 2009, Pages 1876-1880

  Zhang, Wen ^a   Shi, Qun ^a   Wu, Dong Hai ^a   Bao, Chun De ^a   Yang, Nan Ping ^a   Li, Zhan Guo ^a   Zhu, Ping ^a   Zhang, Xiao ^a   Huang, Ci Bo ^a   He, Dong Yi ^a   Ye, Zhi Zhong ^a   Tao, Yi ^a   Fang, Yong Fei ^a   Gu, Jie Ruo ^a   Wu, Hua Xiang ^a   Sun, Ling Yun ^a   Yang, Xiu Yan ^a   Huang, Feng ^a   Xu, Hu Ji ^a   Zhao, Dong Bao ^a   Zhang, Miao Jia ^a   Zheng, Yi ^a   Ai, Mai Xing ^a   Lu, Jun ^a   Zhang, Feng Chun ^a   more..

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Methotrexate; Rheumatoid arthritis; TNF inhibitor

Indexed keywords

ANTIRHEUMATIC AGENT; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84871309049     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2009.27.002     Document Type: Article

References (12)

1. Wolfe F, Zwillich SH. The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1600 patients with rheumatoid arthritis. Arthritis Rheum, 1998, 41: 1072-1082.
2. Felson DT, Anderson JJ. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum, 1995, 38: 727-735.
3. Fex E, Jonsson K, Johnson U, et al. Development of radiographic damage during the first 5-6 yr of rheumatoid arthritis: a prospective follow-up study of a Swedish cohort. Br J Rheumatol, 1996, 35: 1106-1115.
4. Fuchs HA, Kaye JJ, Callahan LF, et al. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol, 1989, 15: 585-591.
5. Möttönen TT. Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. Ann Rheum Dis, 1988, 47: 648-653.
6. Brennan FM, Maini RN, Feldmann M. TNFα-a pivotal role in rheumatoid arthritis? Br J Rheumatol, 1992, 31: 293-298.
7. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet, 2008, 372: 375-382.
8. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med, 1999, 340: 253-259.
9. Maini RN, St Clair EW, Breedveld F, et al. Randomised phase III trial of infliximab combined with ongoing methotrexate in the treatment of rheumatoid arthritis with persistent disease activity. Lancet, 1999, 354: 1932-1939.
10. Lipsky PE, van der Heijde DM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med, 2000, 343: 1594-1602.
11. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum, 2003, 48: 35-45.
12. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum, 1988, 31: 315-324.